<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273948</url>
  </required_header>
  <id_info>
    <org_study_id>PPHM 1003</org_study_id>
    <nct_id>NCT01273948</nct_id>
  </id_info>
  <brief_title>Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection</brief_title>
  <official_title>A Randomized, Active-Control Phase II Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic Hepatitis C Virus Genotype 1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peregrine Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, open-label, active-control Phase II pilot trial of bavituximab&#xD;
      combined with ribavirin for initial treatment of chronic HCV genotype 1 infection. Eligible&#xD;
      patients with normal coagulation, hematological, and renal function will undergo a&#xD;
      screening/washout period of up to 28 days, followed by randomization to receive weekly&#xD;
      bavituximab or PEG-IFN alpha-2a therapy for 12 weeks, both with twice-daily ribavirin.&#xD;
&#xD;
      The primary endpoint of this study is the proportion of patients who show a greater than or&#xD;
      equal to 2-log10 IU reduction in plasma HCV RNA level after 12 weeks of treatment (early&#xD;
      virological response; EVR).&#xD;
&#xD;
      Secondary endpoints include the proportion of patients with an undetectable HCV RNA level&#xD;
      after 12 weeks of treatment; the proportion of patients who show a reduction in HCV RNA level&#xD;
      of greater than or equal to 2 log10 IU after 4 weeks of treatment, viral kinetics for&#xD;
      individual patients over time, and comprehensive evaluation of the safety and tolerability of&#xD;
      bavituximab infusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: The primary objective of this study is to assess the effect of 12 weeks of&#xD;
      initial treatment with bavituximab versus PEG-IFN, each combined with ribavirin, on plasma&#xD;
      HCV RNA level in patients with chronic HCV genotype 1 infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Hepatitis C Virus RNA</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary endpoint is the proportion of patients who show a greater or equal 2-log(10) IU reduction in HCV RNA level at Study Week 12 (early virological response, EVR).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Bavituximab 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight &lt;75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bavituximab 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight &lt;75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegylated interferon (PEG-IFN)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight &lt;75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bavituximab</intervention_name>
    <description>Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight &lt;75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or&#xD;
Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight &lt;75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or</description>
    <arm_group_label>Bavituximab 0.3 mg/kg</arm_group_label>
    <arm_group_label>Bavituximab 3 mg/kg</arm_group_label>
    <other_name>Bavituxmab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon (PEG-IFN)</intervention_name>
    <description>Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight &lt;75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks</description>
    <arm_group_label>Pegylated interferon (PEG-IFN)</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female between the ages of 18 and 65 years&#xD;
&#xD;
          2. Chronic hepatitis C virus (HCV) genotype 1 infection&#xD;
&#xD;
          3. HCV RNA level &gt;10,000 IU/mL&#xD;
&#xD;
          4. Chronic HCV infection, defined as:&#xD;
&#xD;
               -  Previous documentation of positive HCV serology (HCV antibody or RNA) at least 6&#xD;
                  months (24 weeks) previously, or&#xD;
&#xD;
               -  Positive HCV serology (HCV antibody or RNA) with a prior remote (more than 6&#xD;
                  months previously) risk factor for acquisition of HCV or&#xD;
&#xD;
               -  Historical biopsy consistent with chronic HCV infection&#xD;
&#xD;
          5. No clinically significant abnormalities in hematology, coagulation, or chemistry&#xD;
             variables:&#xD;
&#xD;
               -  Hemoglobin &gt;12 g/dL for women; &gt;13 g/dL for men&#xD;
&#xD;
               -  Total white cell count &gt;3000/mm3 and absolute neutrophil count &gt;1500/mm3&#xD;
&#xD;
               -  Platelets &gt;100,000/mm3&#xD;
&#xD;
               -  Prothrombin time (PT) and/or international normalized ratio (INR) less than or&#xD;
                  equal to 1.2 times the local upper limit of normal (ULN)&#xD;
&#xD;
               -  Conjugated (direct) bilirubin less than or equal to 1.5 times the ULN&#xD;
&#xD;
               -  Serum creatinine within normal limits&#xD;
&#xD;
               -  Thyroid-stimulating hormone (TSH) and free thyroxine (T4) within normal limits&#xD;
&#xD;
          6. Female patients: negative urine pregnancy test&#xD;
&#xD;
          7. Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous interferon-based antiviral therapy for chronic HCV infection&#xD;
&#xD;
          2. Previous treatment with known immunogenic drugs&#xD;
&#xD;
          3. Concomitant human immunodeficiency (HIV) or hepatitis B virus (HBV) infection&#xD;
&#xD;
          4. Cause of liver disease other than chronic HCV infection, such as autoimmune or&#xD;
             alcoholic liver disease&#xD;
&#xD;
          5. Decompensated clinical liver disease, including a history of encephalopathy, bleeding&#xD;
             esophageal or gastric varices, or ascites&#xD;
&#xD;
          6. Recipient of liver or other solid-organ transplantation&#xD;
&#xD;
          7. Evidence of clinically significant bleeding, defined as gross hematuria, hemoptysis,&#xD;
             or gastrointestinal bleeding&#xD;
&#xD;
          8. History of bleeding diathesis or coagulopathy (eg, von Willebrand disease or&#xD;
             hemophilia)&#xD;
&#xD;
          9. History of thromboembolic events (eg, deep-vein thrombosis [DVT] or pulmonary&#xD;
             embolism). Previous central venous catheter-related thrombosis is acceptable if there&#xD;
             is resolution recorded at least 12 months before enrollment.&#xD;
&#xD;
         10. Requirement for concurrent treatment with oral or parenteral anticoagulants or&#xD;
             hormones (estrogen-containing contraceptives, hormone replacement, antiestrogen&#xD;
             agents, progestins)&#xD;
&#xD;
         11. Condition requiring daily therapy with antiplatelet agents (eg, thienopyridines,&#xD;
             dipyridamole, cilostazol; cardiovascular prophylaxis with aspirin is allowed) or&#xD;
             corticosteroids&#xD;
&#xD;
         12. Investigational therapy within 28 days before the first planned dose of study drug&#xD;
&#xD;
         13. Major surgery within 28 days before the first planned dose of study drug&#xD;
&#xD;
         14. Uncontrolled intercurrent disease (eg, diabetes, hypertension, thyroid disease)&#xD;
&#xD;
         15. Ongoing angina pectoris or other symptoms of coronary artery disease (CAD); history of&#xD;
             stroke, or transient ischemic attack (TIA)&#xD;
&#xD;
         16. History of suicidal ideation or attempt&#xD;
&#xD;
         17. Condition requiring treatment (past or current) with coumarin-type agents&#xD;
&#xD;
         18. Cardiac arrhythmia requiring medical therapy&#xD;
&#xD;
         19. Serious nonhealing wound (including wound healing by secondary intention, ulcer, or&#xD;
             bone fracture)&#xD;
&#xD;
         20. Cancer, autoimmune disease, or any disease or concurrent therapy known to cause&#xD;
             significant alteration in immune function (corticosteroids are allowed before study&#xD;
             enrollment and during the study to treat an AE)&#xD;
&#xD;
         21. Female patients and female partners of male patients: pregnancy, lactation, or&#xD;
             inability/unwillingness to practice effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Nuttall, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Peregrine Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LTD Vakhtang Bochorishvili Anticeptic Centre</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Bavituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

